131I-meta-iodobenzylguanidine scintigraphy of neuroblastomas

Munkner, T

doi:10.1016/s0001-2998(85)80023-4

Cited by 54 publications

(18 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this article, we have reported our experience in detecting lesions in various anatomical locations in patients with neuroblastoma by means of different imaging modalities. The rationale for this approach is that several imaging techniques are currently available for the diagnostic evaluation of children with neuroblastoma, but the relative role of each is still under investigation [1][2][3][4][5][6][7][8][9][10].…”

Section: Discussionmentioning

confidence: 99%

“…However, these imaging techniques may fail to simultaneously detect multiple lesions when these are located in different anatomical sites. This drawback may be overcome using iodine-131 metaiodobenzylguanidine (MIBG) whole-body scintigraphy, which allows the detection of neuroblastoma lesions located in multiple, unusual and/or unexpected sites [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Iodine-131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: comparison with computed tomography and ultrasonography

et al. 1993

View full text Add to dashboard Cite

Iodine-131 metaiodobenzylguanidine (MIBG) scintigraphy, computed tomography (CT) and ultrasonography (US) were used to localize tumour lesions in 28 children with histologically proven neuroblastoma. Overall, a total of 73 lesions were detected on imaging studies. MIBG scintigraphy, CT and US localized 63 (86%), 49 (67%) and 36 (49%) of these lesions, respectively. The findings of the three imaging techniques were concordant in respect of only 31 (42%) of the lesions. The best agreement among MIBG scintigraphy, CT and US was observed for abdominal lesions (the techniques were concordant for 22 of 23 lesions, i.e. 96%). MIBG scintigraphy detected nine out of ten (90%) liver metastases, but agreement with CT and US was observed in only six instances (60%). The imaging findings were concordant in respect of only two (33%) out of six lymph node metastases; the MIBG scan was normal in the other four cases. Imaging agreement was observed for a lesion located in the pelvis. MIBG and CT findings were concordant in four lesions located in the chest, but US was not performed. MIBG scintigraphy depicted the majority (96%) of the skeletal lesions (23/24); CT showed five of these, but, again, US was not performed. The imaging findings were not concordant as regards the remaining five lesions located in different anatomical sites. The results indicated that MIBG imaging is more sensitive that CT and US in localizing the majority of neuroblastoma lesions. Since the metastatic spread of neuroblastoma is unpredictable, we recommend MIBG scintigraphy as the initial imaging modality for staging of these patients.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Iodine-131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: comparison with computed tomography and ultrasonography

et al. 1993

View full text Add to dashboard Cite

show abstract

“…The long change between the erythrocytes and plasma, and other half-life and low photon energy are advantageous [8-lo]. tissues remain to be further explored [42].…”

Section: The Metabolism Of Radlolodlnated Mlbcmentioning

confidence: 99%

“…There are theoretical reasons to believe that the high The platelets have an active amine uptake mechanism abundance of low-energy Auger electrons may be ideal related to that found in adrenergic tissues, and indeed, for delivering therapeutic doses of radiation to isolated platelets do show MIBG concentration [42,43]. cells or cell clusters of neuroblastoma that may occur in The intense transient pulmonary uptake of 123-I-MIBG the bone marrow.…”

Section: The Metabolism Of Radlolodlnated Mlbcmentioning

confidence: 99%

Radiochemistry, biochemistry, and kinetics of ¹³¹I‐metaiodobenzylguanidine (MIBG) and ¹²³I‐MIBG: Clinical implications of the use of ¹²³I‐MIBG

Shapiro

Gross²

1987

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Metaiodobenzylguanidine (MIBG) is actively concentrated in adrenergic neuroendocrine tissues and tumors by an active, energy- and sodium-dependent, high-affinity, saturable mechanism. This has proved successful, when labeled with 131-I or 123-I, in scintigraphically depicting pheochromocytomas and neuroblastomas. For imaging purposes 123-I has multiple advantages over 131-I; the gamma ray energy is ideal for modern instruments, the decay by electron capture limits the particulate emissions, and the short half-life reduces the radiation burden. It is thus possible to use doses of 123-I-MIBG 20 times as large as doses of 131-I-MIBG with equivalent absorbed radiation doses. Disadvantages of 123-I include the cost and difficulties in the regular delivery of this short-lived radionuclide. For most imaging purposes 123-I-MIBG is the optimal agent if logistical problems in its supply can be overcome.

show abstract

“…Competent cells take up MIBG mainly by an energy-dependent mechanism [1]. Scintigraphy with iodine-123-or iodine-131-labelled MIBG has become a well-established and highly sensitive and specific method in the diagnosis and staging of neuroblastoma [2,3].…”

mentioning

confidence: 99%

False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma

Biasotti

Garaventa

Villavecchia

et al. 2000

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

131I-meta-iodobenzylguanidine scintigraphy of neuroblastomas

Cited by 54 publications

References 5 publications

Iodine-131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: comparison with computed tomography and ultrasonography

Iodine-131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: comparison with computed tomography and ultrasonography

Radiochemistry, biochemistry, and kinetics of ¹³¹I‐metaiodobenzylguanidine (MIBG) and ¹²³I‐MIBG: Clinical implications of the use of ¹²³I‐MIBG

False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma

Contact Info

Product

Resources

About

131I-meta-iodobenzylguanidine scintigraphy of neuroblastomas

Cited by 54 publications

References 5 publications

Iodine-131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: comparison with computed tomography and ultrasonography

Iodine-131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: comparison with computed tomography and ultrasonography

Radiochemistry, biochemistry, and kinetics of 131I‐metaiodobenzylguanidine (MIBG) and 123I‐MIBG: Clinical implications of the use of 123I‐MIBG

False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma

Contact Info

Product

Resources

About

Radiochemistry, biochemistry, and kinetics of ¹³¹I‐metaiodobenzylguanidine (MIBG) and ¹²³I‐MIBG: Clinical implications of the use of ¹²³I‐MIBG